QQ客服 官方微博 反馈留言

浏览/检索结果: 共5条，第1-5条 帮助 已选(0)清除 条数/页：5101520253035404550556065707580859095100   排序方式：请选择作者升序作者降序题名升序题名降序发表日期升序发表日期降序提交时间升序提交时间降序 Spectroscopic methodologies and molecular docking studies on the interaction of the soluble guanylate cyclase stimulator riociguat with human serum albumin 期刊论文 BIOSCIENCE TRENDS, 2018, 卷号: 12, 期号: 4, 页码: 369-374 作者:  Ma, Rui;  Li, Zhenyu;  Di, Xiaxia;  Guo, Dongxiao;  Ji, Jianbo 收藏  |  浏览/下载：4/0  |  提交时间：2019/12/11 Riociguat  human serum albumin (HSA)  interaction  molecular docking   Comparison of hemodynamic parameters in treatment-naive and pre-treated patients with pulmonary arterial hypertension in the randomized phase III PATENT-1 study 期刊论文 2017, 卷号: 36, 期号: 5, 页码: 509-519 作者:  Galiè Nazzareno;  Grimminger Friedrich;  Grünig Ekkehard;  Hoeper Marius M;  Humbert Marc 收藏  |  浏览/下载：3/0  |  提交时间：2020/01/04 pulmonary arterial  hypertension  clinical trial  pulmonary  riociguat  soluble guanylate  cyclase stimulator   Riociguat: a soluble guanylate cyclase stimulator for the treatment of pulmonary hypertension 期刊论文 2017, 卷号: 11, 页码: 1195-1207 作者:  Lian Tian-Yu;  Jiang Xin;  Jing Zhi-Cheng 收藏  |  浏览/下载：9/0  |  提交时间：2020/01/04 CTEPH  PAH  pulmonary hypertension  riociguat  sGC stimulator   Use of clinically relevant responder threshold criteria to evaluate the response to treatment in the Phase III PATENT-1 study 期刊论文 JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2015, 卷号: 34, 期号: 3 作者:  Langleben, David;  Galie, Nazzareno;  He, Jianguo;  Huang, Yigao;  Humbert, Marc 收藏  |  浏览/下载：9/0  |  提交时间：2019/12/19 pulmonary arterial hypertension  riociguat  soluble guanylate cyclase stimulator  treatment response  responder threshold criteria   Use of clinically relevant responder threshold criteria to evaluate the response to treatment in the Phase III PATENT-1 study 期刊论文 2015, 卷号: 34, 期号: 3, 页码: 338-347 作者:  Langleben, David;  Galie, Nazzareno;  He, Jianguo;  Huang, Yigao;  Humbert, Marc 收藏  |  浏览/下载：5/0  |  提交时间：2020/01/13 pulmonary arterial hypertension  riociguat  soluble guanylate cyclase stimulator  treatment response  responder threshold criteria